To read this content please select one of the options below:

Managing escalating events: a case study from the pharmaceutical industry

Kevin John Burnard (Ancell School of Business, Western Connecticut State University, Danbury, Connecticut, USA)

Continuity & Resilience Review

ISSN: 2516-7502

Article publication date: 3 May 2022

Issue publication date: 8 July 2022

127

Abstract

Purpose

This paper presents a case study of the response of a pharmaceutical goods manufacturer to an unexpected disruptive event. Following a period of heavy rainfall, a small town within the UK was quickly overwhelmed by localised flash flooding. The sudden rise in ground water overwhelmed local drainage systems and caused flooding in several areas of the town. One of the impacted areas included the manufacturing facilities of a pharmaceutical goods producer. This case study explores the subsequent response of the organisation to the event.

Design/methodology/approach

Based on direct interviews and supporting documentation, this case study analyses the organisation's response and recovery activities in the face of escalating impacts. Drawing on identified theory, specific attention is placed on characterising severe events and the challenges of coordinating response activities.

Findings

Drawing on the evidence of this case study, this paper highlights the identified features of an effective response within escalating events. Without this response, events such as those experienced by the case study organisation carry the distinct possibility of developing into large scale disruptions. This study highlights the importance of established channels of authority and the ability to identify and contain impacts.

Originality/value

This paper outlines some of the key considerations and operational priorities within response activities. These priorities support the effective identification and resolution of disruptive events and their associated impacts.

Keywords

Citation

Burnard, K.J. (2022), "Managing escalating events: a case study from the pharmaceutical industry", Continuity & Resilience Review, Vol. 4 No. 2, pp. 176-191. https://doi.org/10.1108/CRR-10-2021-0035

Publisher

:

Emerald Publishing Limited

Copyright © 2022, Emerald Publishing Limited

Related articles